<DOC>
	<DOCNO>NCT01485835</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , ganetespib bortezomib cancer . The investigator determine side effect different dose level ganetespib give alone effect cancer alone . The investigator also determine side effect ganetespib different dose level give combination bortezomib effect combination cancer . The study measure level drug blood bone marrow well . Bortezomib proteasome inhibitor approve US Food Drug Administration ( FDA ) use treatment multiple myeloma . The brand name bortezomib Velcade® . Ganetespib consider `` investigational '' receive approval Food Drug Administration general use , although previously test human .</brief_summary>
	<brief_title>A Phase I Study Ganetespib +/- Bortezomib Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Males female , age 18 year old . Diagnosis relapse refractory multiple myeloma ( MM ) documentation least 2 prior therapy must include bortezomib immunomodulatory agent ; maximum number prior regimen . Patients measurable disease define least one following : 1 . Serum Mprotein ≥ 0.5 g/dl ( ≥ 5 g/l ) 2 . Urine Mprotein ≥ 200 mg/24 h 3 . Serum free lightchain ( FLC ) assay : Involved FLC level ≥ 10 mg/dl ( ≥ 100 mg/l ) abnormal serum free light chain ratio ( &lt; 0.26 &gt; 1.65 ) 4 . Measurable plasmacytoma ( prior biopsy acceptable , measure within 28 day first study drug administration ) . Subject Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 OR Karnofsky ≥ 60 % performance status . Females childbearing potential* : Confirmation subject pregnant must establish negative serum βhuman chorionic gonadotropin ( βhCG ) pregnancy test result obtain screening . Pregnancy test require postmenopausal surgically sterilize woman . FCBP must also agree ongoing pregnancy test . Men must agree use latex condom sexual contact FCBP even successful vasectomy . * ( FCBP A female childbearing potential sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ) . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( accordance national local subject privacy regulation ) . Voluntary write informed consent performance studyrelated procedure part routine medical care understanding consent may withdraw subject time without prejudice future medical care . Inclusion clinical laboratory criteria 1 . Absolute neutrophil count ( ANC ) ≥ 1,000 cells/dL ( 1.0 x 10⁹/L ) ( Growth factor use within 7 day first drug administration ) 2 . Platelet count ≥ 75 x 10⁹/L ( platelet transfusion use within 4 day first drug administration ) 3 . Hemoglobin ≥ 8.0 g/dl 4 . Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 1.5 x upper limit normal ( ULN ) 5 . Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 50 mL/min ( CockcroftGault calculation ) 6 . Total bilirubin ≤ 1.5 x ULN 7 . Serum calcium ( correct serum albumin ) ionize calcium ≥ low limit normal ( LLN ) ( treatment hypercalcemia allow subject may enroll hypercalcemia return normal standard treatment ) . Patients receive chemotherapy , immunomodulatory drug ( e.g. , lenalidomide , thalidomide pomalidomide ) , immunotherapy , radiation therapy , investigational drug ( ) within 14 day enrollment recover side effect therapy least grade 1 . Localized radiation therapy single site within 7 day acceptable . Prior therapy heat shock protein 90 ( HSP90 ) inhibitor . Daily requirement corticosteroid ( except inhalational corticosteroid ) ; prednisone ≤ 10mg/day equivalent permit medical condition . Prior peripheral stem cell transplant within 12 week first dose study treatment . Use venous access device make material silicone infusion ganetespib . Patients device eligible long device use infusion . History severe allergic hypersensitivity reaction excipients ( e.g. , Polyethylene glycol [ PEG ] 300 Polysorbate 80 ) . Baseline correct QT interval ( QTc ) &gt; 470 msec previous history QT prolongation take medication . Ventricular ejection fraction ( Ef ) ≤ 50 % baseline . History document congestive heart failure ( CHF ) , New York Heart Association class II/III/IV , history dyspnea , orthopnea edema require current treatment angiotensin convert enzyme inhibitor , angiotensin II receptor blocker , betablockers diuretic . NOTE : Use medication treatment hypertension allow . Highrisk uncontrolled arrhythmia ( ventricular tachycardia , highgrade atrioventricular [ AV ] block , supraventricular arrhythmia adequately ratecontrolled ) require current treatment follow antiarrythmic drug : flecainide , moricizine propafenone . History active current coronary artery disease unstable angina . Peripheral neuropathy ≥ grade 2 . Treatment chronic immunosuppressant ( e.g. , cyclosporine follow transplantation ) . Uncontrolled intercurrent illness include , limited , human immunodeficiency virus ( HIV ) positive subject receive combination antiretroviral therapy , severe systemic infection , psychiatric illness/social situation would limit compliance study requirement . Other medication , severe acute/chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>Ganetespib</keyword>
</DOC>